Morning Briefing
Summaries of health policy coverage from major news organizations
Research Roundup: The Latest Science, Discoveries, And Breakthroughs
CIDRAP: Antiviral Drug Ensitrelvir Shows Promise In Preventing Household COVID Spread
People who started taking the antiviral drug ensitrelvir within 72 hours after a household member tested positive for COVID-19 were significantly less likely to be infected, according to results from an international phase 3 clinical trial presented last week at the Conference on Retroviruses and Opportunistic Infections in San Francisco. (Van Beusekom, 3/19)
CIDRAP: Pulmonary Therapy Shows Promise For Long-COVID Patients
Pulmonary rehabilitation (PR), including breath control exercises, can improve lung function in long COVID patients after only 4 to 8 weeks, according to a study in Therapeutic Advances in Respiratory Disease. (Soucheray, 3/19)
CIDRAP: 3 Vaccine Doses Cut Long-COVID Risk By Over 60%, Analysis Suggests
In a Swedish cohort, the risk of long COVID was much lower for vaccinated than unvaccinated participants in the year after infection, even when restricting the analyses to subgroups based on variant, age, sex, and previous infection status, estimates a study published last week in the Journal of Infectious Diseases. (Van Beusekom, 3/17)
MedPage Today: Dementia Drug Doesn't Help Long COVID Fatigue, Psychological Symptoms
Use of donepezil (Aricept), an acetylcholinesterase inhibitor, for 3 weeks failed to demonstrate efficacy in treating fatigue and psychological symptoms of long COVID in a randomized trial from Japan. (Brunk, 3/17)
ScienceDaily: Latest Alzheimer's Drug Shown Less Effective In Females Than Males
A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was totally ineffective in females. (McGill University, 3/18)
CIDRAP: Estimates: Jynneos Mpox Vaccine 84% And 35% Effective In People Without, With HIV
One dose of the Jynneos vaccine was 58% effective against mpox infection overall and 84% in people without HIV, but only 35% in those with HIV, according to an observational combined study published yesterday in The Lancet Infectious Diseases. (Van Beusekom, 3/19)
CIDRAP: U Penn Survey Shows Only 56% Of Americans Understand Drinking Raw Milk Is Risky
A new survey from the Annenberg Public Policy Center (APPC) at the University of Pennsylvania shows that 56% of US adults know that drinking unpasteurized, or raw, milk is less safe than drinking pasteurized milk, but there have been no significant changes in public perceptions of raw milk in the past 6 month, despite detections of H5N1 avian flu virus in unpasteurized milk. (Soucheray, 3/17)
